Increase In Initial Order For COVID-19 Supplement.

Pharmaceuticals companies have announced that many of the distributors like Swiss Pharma, Aark Pharma has increased their initial order volume for ArtemiC Rescue, an anti-inflammatory product from COVID-19, by 85%.

MGC said it has enough manufacturing capacity to complete the first batch of approximately $ 425,000.

“This additional agreement will give more people access to the natural therapeutic benefits of the dietary supplement and alleviate suffering following the successful results of Phase II trials in December,” said CEO Robie Zomer.

Many Pharma companies can now have the exclusive right to market Artemis worldwide, with a particular focus on countries that are currently reporting high numbers of coronavirus (COVID-19) cases. The framework agreement provides for a minimum bulk order of 40,000 units per quarter.

Aark Pharma


Meanwhile, ArtemiC has stood the test of time in phase II clinical trials that have been shown to prevent COVID-19 patients from worsening and help them achieve faster clinical improvement. It has also been found to be safe and does not cause adverse drug reactions.

The dietary supplement has anti-inflammatory effects that have been shown to reduce and prevent cytokine storms in patients hardest hit by COVID-19.

It contains four ingredients: artemisinin, curcumin, Boswellia Serrata, and vitamin C.

As the cases are increasing day by day of covid-19 and hence are the requirements of the medicine increasing. All of the pharmaceutical companies are increasing their stock of medicines as it is likely that the third wave 

Comments

Popular posts from this blog

Generic Medications Drugs Supplier

The Best Cancer Medicine Distributors In Delhi

Cardiac Arrest Different from A Heart Attack